Fact Sheets

# Fact Sheet: President Donald J. Trump Announces Major Developments in Bringing Most-Favored-Nation Pricing to American Patients

The White House
November 6, 2025

ADVANCING MOST-FAVORED-NATION (MFN) PRICING: Today, President Donald J. Trump announced the latest in a series of the most significant actions ever taken by our Federal government to lower prescription drug prices, unveiling agreements with pharmaceutical manufacturers Eli Lilly and Company and Novo Nordisk to dramatically reduce the prices Americans pay for some of the world’s most popular drugs.

- The agreement represents a historic reduction in prices for Americans on the two drugs with the highest annual expenditures in the United States, both of which help adults struggling with diabetes, heart disease (Ozempic and Wegovy only), obesity, and other conditions.
  - The prices of Ozempic and Wegovy will fall from $1,000 and $1,350 per month, respectively, to $350 when purchased through TrumpRx.
  - The price of Zepbound and Orforglipron, if approved, will fall from $1,086 per month to an average of $346 when purchased through TrumpRx.
  - In the event that the FDA later approves the Wegovy pill, or certain similar “GLP-1” drugs in each company’s pipeline intended to be taken orally rather than as a shot, the initial dose of those drugs will be priced at $150 per month through TrumpRx.
- The historic reduction in prices negotiated by President Trump will enable Medicare and Medicaid to cover obesity drugs for adults at a dramatically lower cost to taxpayers than that proposed by the Biden Administration.
  - The Medicare prices of Ozempic, Wegovy, Mounjaro, and Zepbound will be $245, less than half the prices proposed by the Biden Administration on such drugs. State Medicaid programs will also have access to these medications at these prices.
  - These low prices will enable Medicare to cover Wegovy and Zepbound for patients with obesity and related comorbidities for the first time.
  - Medicare beneficiaries will pay a co-pay of just $50 per month.
- Additionally, the agreement provides for reduced costs on other Eli Lilly and Novo Nordisk medicines when purchased through TrumpRx. For example:
  - Eli Lilly will provide Emgality, a treatment for migraines, at $299 per pen, a discount of $443 off of the list price.
  - Eli Lilly will provide Trulicity, a commonly used diabetes medicine, at $389 per month, a discount of $598 off of the list price.
  - Novo Nordisk will provide widely-used insulin products, including NovoLog and Tresiba, at $35 per month of supply.
- The agreement also provides that Eli Lilly and Novo Nordisk will guarantee MFN prices on all new medicines that they bring to market, repatriate increased foreign revenue on existing products, and provide every State Medicaid program in the country access to MFN drug prices on their products.

INVESTING IN AMERICA TO SECURE PHARMACEUTICAL SUPPLY CHAINS: Eli Lilly and Novo Nordisk are also announcing large investments to expand U.S. manufacturing capacity.

- Novo Nordisk has committed an additional $10 billion investment to strengthen its domestic footprint, including producing the Wegovy tablet, if approved, end-to-end in the U.S.
- Under President Trump’s leadership, Eli Lilly has announced at least $27 billion in new U.S. manufacturing investments.

MAKING AMERICA HEALTHY AGAIN: President Trump promised to ensure the American healthcare system is promoting health and addressing the root causes of chronic disease. Today’s announcements represent historic progress on meeting this promise.

- The Centers for Disease Control and Prevention (CDC) estimate the prevalence of obesity among American adults to be 40%.
- Obesity is one of the key drivers of chronic disease, increasing the risk of type 2 diabetes, hypertension, heart disease, strokes, and certain cancers, among other conditions.
- Today’s announcement makes available potentially life-changing medications to adults struggling with obesity, representing a historic opportunity to reverse the obesity epidemic and associated chronic disease crisis when coupled with lifestyle changes to preserve and improve health gains long-term.
- The Administration remains committed to a comprehensive Make America Healthy Again approach that realigns incentives, fosters private-sector collaboration, increases public awareness of the importance of diet and exercise, and advances critical research.

ENDING GLOBAL FREELOADING ON AMERICAN PHARMACEUTICAL INNOVATION: President Trump is taking decisive action to rebalance a system that has allowed pharmaceutical manufacturers to offer low prices to other wealthy nations while charging Americans significantly higher prices.

- According to recent data, the prices Americans pay for brand-name drugs are more than three times the price other Organization for Economic Cooperation and Development nations pay, even after accounting for discounts manufacturers provide in the U.S.
- The United States has less than five percent of the world’s population, yet roughly 75% of global pharmaceutical profits come from American taxpayers.
- Drug manufacturers benefit from generous research subsidies and enormous healthcare spending by the U.S. Government. Instead of passing that benefit through to American consumers, drug manufacturers then discount their products abroad to gain access to foreign markets and subsidize those discounts through high prices charged in America. Americans are subsidizing drug-manufacturer profits and foreign health systems, both in development and once the drugs are sold.

DELIVERING ON PROMISES TO PUT AMERICAN PATIENTS FIRST: President Trump is delivering on promises for American patients that the political establishment did not believe were possible.

- On May 12, 2025, President Trump signed an Executive Order titled: “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients” directing the Administration to take numerous actions to bring American drug prices in line with those paid by similar nations.
- On July 31, 2025, President Trump sent letters to leading pharmaceutical manufacturers outlining the steps they must take to bring down the prices of prescription drugs in the United States to match the lowest price offered in other developed nations.
- Since September 30, 2025, President Trump has announced five deals with major pharmaceutical manufacturers to bring prices in line with those paid in other developed nations, which will provide substantial price relief on numerous products taken by millions of Americans.
- President Trump has been relentless in his effort to address the unfair and outrageous prices Americans pay for prescription drugs:
  - President Trump: “In case after case, our citizens pay massively higher prices than other nations pay for the same exact pill, from the same factory, effectively subsidizing socialism abroad with skyrocketing prices at home. So we would spend tremendous amounts of money in order to provide inexpensive drugs to another country. And when I say the price is different, you can see some examples where the price is beyond anything — four times, five times different.”

## Related

- ### Fact Sheet: President Donald J. Trump Launches TrumpRx.gov to Bring Lower Drug Prices to American Patients

  Fact Sheets
  February 5, 2026

- ### Fact Sheet: President Donald J. Trump Announces Largest Developments to Date in Bringing Most-Favored-Nation Pricing to American Patients

  Fact Sheets
  December 19, 2025

- ### Fact Sheet: President Donald J. Trump Announces Second Deal to Bring Most-Favored-Nation Pricing to American Patients

  Fact Sheets
  October 10, 2025

- ### Fact Sheet: President Donald J. Trump Announces First Deal to Bring Most-Favored-Nation Pricing to American Patients

  Fact Sheets
  September 30, 2025

- ### Fact Sheet: President Donald J. Trump Announces Actions to Get Americans the Best Prices in the World for Prescription Drugs

  Fact Sheets
  July 31, 2025

Notifications